Covance is an international scientific services company and is known as a Contract Research Organization (CRO). The company is contracted by pharmaceutical, biotechnology, agricultural and medical device companies to perform needed services involving drug and chemical development.
Covance is the second largest CRO in the world in terms of revenue, earning $1.36 billion in nine months of 2008 ending September 30, 2008. In 2007 total revenue was $1.6 billion and in 2006 the company obtained 10% of the total global CRO revenue with revenue of $1.5 billion. Yearly total revenue for the company has increased between 2005 and 2007 by 23.4% due to increases in demand, capacity expansion, acquisitions and selling of one of its businesses. Revenue for Covance is driven primarily by the demand for outsourcing of research and development by pharmaceutical and biotechnology companies., Covance has also increased operating and net income margins between 2003 and 2007 by 16.2% and 29% respectively.
Amidst high development costs, companies are increasingly turning to CROs to help move through the drug development and heavily regulated process to bring products to market quicker and and at a lower cost. To take advantage of this trend Covance acquired three companies from 2005 to 2007 totaling $81.9 million and has increased its revenue from international deals by 10% over the past year to $85 million.
Covance provides drug development solutions from preclinical (before human testing) through commercialization for six main areas: biotechnology, pharmaceuticals, food and drug supplements, general research and vaccine testing.
Its services are divided into Early Development and Late Stage Development segments and include: research products, antibody products and services, nonclincal development services, risk assessment services, clinical pharmacology services, central laboratory services, cardiac safety services, clinical development and commercialization services.
|Operating and Net Income Margins |
|Net Income Margin||8.1%||9.6%||10.0%||10.8%||11.4%|
Covance reported $1.36 billion in total revenue in the first three quarters of 2008. The company's revenue increased by 15.4% in 2007 (12.8% when excluding foreign currency fluctuations) to $1.6 billion. This increase was partially due to currency movements, but were primarily determined by a 20% increase in the company's early development segment to $778 million (in revenue) and a 6.3% increase in its late-stage development segment to $769 million (in revenue). Strong growth in the company's clinical development services outweighed decreases in its central laboratory, cardiac safety and commercialization services. Covance also realized gains of $0.4 million due to a minority equity position (approximately 20%) in Bio-Imaging technologies and $2 million due to a minority position (approximately 47%) in Noveprim Limited in 2007. As of Dec. 31, 2007 Covance had no debt and $319 million in cash and cash equivalents. Its operating margin has increased 16.2% over the past five years to 14.8% and its net income margin has increased by 29% over the same period to 11.4%. In February 2007 Covance's Board of Directors authorized a 3 million share buyback plan and at the end of 2007 2.3 million remained for purchase under the plan.
Net revenue increased 12.3% in 2006 to $1.34 billion. Revenue changes were partially determined by acquisitions, but were primarily due to growth in its early development and late-stage development segments. Growth in the early development segment was fueled by strong performance in its global toxicology, chemistry and clinical pharmacology services, resulting in a 12.6% increase in net revenue. Strong performance in the company's central laboratory services resulted in a net revenue increase in its late-stage development segment of 12.2%.
Net revenues increased 16.9% in 2005 to $1.19 billion. Net revenue growth was supported by strong performance across service offerings in both segments, resulting in a 17.5% growth in the company's early development segment and a 16.4% net revenue increase in its late-stage development segment.
In November of 2007 Covance sold its Electrocardiogram (ECG) business ("Cardiac Safety Services"), which was part of its Late Stage Development segment to eResearch Technology Inc. The company received an initial payment of $35.2 million and entered into a ten year agreement under which Covance will continue to offer the cardiac safety services. The deal also stated that Covance will be eligible to receive up to an additional $14 million relating to transferred backlog and future contracts.
To strengthen its Early Development segment, Covance acquired the clinical pharmacology sites of GFI Clinical Services in 2005 for $6.2 million and the clinical pharmacology sites of Radiant Research Inc. in 2006 for $66.6 million. Also, in 2006 the company acquired Signet Laboratories Inc. for $9.1 million.
Early Development Services (47.7% of FY 2007 Revenue, 60.5% of FY 2007 Operating Income)
Covance's early development services mainly support pre-human testing of animals and in vitro (non-animal models) experiments to develop drug and chemical profiles that if required, will then move into clinical trials. These services generated $778 million in revenue in 2007 and comprise six areas: toxicology, pharmaceutical and nutritional chemistry, bioanalytical, clinical pharmacology and research products. Laboratories exist in Indiana, Wisconsin, Virginia, Germany, Singapore, and the United Kingdom. These services range from testing the effects of compounds on immune systems to the development of research products to aid scientists in compound testing. Early development services utilize StudyTracker, an internet-based program that allows customers of toxicology, bioanalytical, metabolism and reproductive and developmental toxicology services to review study data and schedules on a near real-time basis.
Late Stage Development Services (47.1% of FY 2007 Revenue, 39.5% of FY 2007 Operating Income)
Covance’s late-stage drug development services support human testing of compounds (clinical trials) and commercialization of approved drugs. These services generated $769 million in revenue in 2007 and include central laboratory, clinical development, trial support, and commercialization services. These services range from the initial setup of clinical trials to the (domestic and international) marketing of products. The company has experience conducting clinical trials in North America, Europe, Latin America and the Asia Pacific.
Other Reconciling Items (5.2% of FY 2007 Revenue)
Revenues from other reconciling items are associated with reimbursable out-of-pocket expenses. It also includes depreciation and amortization on corporate fixed assets, as well as corporate expenses such as marketing and communications. These items generated $85.1 million in revenue in 2007.
Gee whiz, and I thouhgt this would be hard to find out.
Articles like these put the conesumr in the driver seat-very important.
In 2006 the total market for CRO services was estimated to be $15 billion. Of this Covance had a share of 10%, which equated to $1.5 billion.
Back in school, I'm doing so much laerning.